Phil Nadeau
Stock Analyst at TD Cowen
(2.74)
# 1,787
Out of 5,165 analysts
25
Total ratings
45.83%
Success rate
31.94%
Average return
Main Sectors:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Buy | $175 → $215 | $183.26 | +17.32% | 7 | Feb 9, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $175 → $200 | $129.85 | +54.02% | 1 | Dec 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $50 → $45 | $18.87 | +138.47% | 1 | Oct 31, 2025 | |
| KURA Kura Oncology | Reiterates: Buy | n/a | $8.72 | - | 1 | Nov 21, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $55 → $65 | $90.51 | -28.18% | 2 | Nov 6, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $125 → $120 | $57.43 | +108.95% | 1 | Aug 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $500 | $466.10 | +7.27% | 7 | Jul 23, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Outperform | n/a | $27.41 | - | 1 | Mar 3, 2023 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | n/a | $16.73 | - | 1 | Jul 7, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | n/a | $6.74 | - | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.71 | - | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.90 | - | 1 | Jul 16, 2018 |
Biogen
Feb 9, 2026
Maintains: Buy
Price Target: $175 → $215
Current: $183.26
Upside: +17.32%
Neurocrine Biosciences
Dec 5, 2025
Maintains: Buy
Price Target: $175 → $200
Current: $129.85
Upside: +54.02%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $50 → $45
Current: $18.87
Upside: +138.47%
Kura Oncology
Nov 21, 2024
Reiterates: Buy
Price Target: n/a
Current: $8.72
Upside: -
Rhythm Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $55 → $65
Current: $90.51
Upside: -28.18%
BioMarin Pharmaceutical
Aug 6, 2024
Maintains: Buy
Price Target: $125 → $120
Current: $57.43
Upside: +108.95%
Vertex Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $450 → $500
Current: $466.10
Upside: +7.27%
Enliven Therapeutics
Mar 3, 2023
Initiates: Outperform
Price Target: n/a
Current: $27.41
Upside: -
MoonLake Immunotherapeutics
Jul 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $16.73
Upside: -
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.74
Upside: -
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.71
Upside: -
Jul 16, 2018
Initiates: Outperform
Price Target: n/a
Current: $6.90
Upside: -